MedTrace Logo

Safety and Efficacy Study of a Eye Drop for Eye Allergy

NCT00889330 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-03-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

alcaftadine

0.25% Ophthalmic Solution, one drop in each eye at each of two visits.

DRUG

Placebo

Vehicle without active, one drop in each eye at each of two visits.

Sponsors & Collaborators

  • Vistakon Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00889330 on ClinicalTrials.gov